In another work, by examining EGFR trajectories in seven breast epithelial cell lines, we developed a physical phenotyping assay termed Transmembrane Receptor Dynamics (TReD) that can assess the metastatic potential of breast cancer cells (Liu et al., 2019a). This evidence concerns the gene EGFR and breast carcinoma.